PMID- 38366621
OWN - NLM
STAT- Publisher
LR  - 20240217
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
DP  - 2024 Feb 15
TI  - Comparative effectiveness of tofacitinib and tumour necrosis factor inhibitors in 
      patients with rheumatoid arthritis in real-world practice: a prospective 
      observational study.
LID - keae109 [pii]
LID - 10.1093/rheumatology/keae109 [doi]
AB  - OBJECTIVE: To assess the effectiveness of tofacitinib vs tumour necrosis factor 
      inhibitors (TNFi) in Korean patients with rheumatoid arthritis (RA). METHODS: The 
      study used data from a single academic referral hospital's registries of biologic 
      disease-modifying anti-rheumatic drugs (bDMARDs) and tofacitinib and examined 
      remission rates based on the disease activity score (DAS)28-erythrocyte 
      sedimentation rate (ESR) after 12 months. Multivariable logistic regression 
      analysis was used to estimate the odds ratio (OR) for achieving remission with 
      tofacitinib compared with TNFi, adjusting for potential confounders. RESULTS: 
      This analysis included 665 patients (200 on tofacitinib and 455 on TNFi) who were 
      followed up for at least 12 months. Of these, 96 patients in the tofacitinib 
      group (48.0%) and 409 patients in the TNFi group (89.9%) were treatment-naive to 
      bDMARDs. Intention-to-treat analysis revealed no significant difference in the 
      remission rates between the two groups (18.0% vs 19.6%, p = 0.640). Multivariable 
      analysis demonstrated comparable remission rates with tofacitinib and TNFi (OR 
      1.204, 95% confidence interval [CI] 0.720-2.013). In the subpopulation naive to 
      JAKi and bDMARD, tofacitinib showed better remission rates than TNFi (OR 1.867, 
      95% CI 1.033-3.377). Tofacitinib had more adverse events (AEs) but similar rates 
      of serious AEs (SAEs) to TNFi. CONCLUSION: In real-world settings, there was no 
      significant difference in remission rates at 12 months between the tofacitinib 
      and TNFi groups. In terms of safety, tofacitinib exhibited a higher incidence of 
      AEs compared with TNFi, while the occurrence of SAEs was comparable between the 
      groups. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02602704.
CI  - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology. All rights reserved. For permissions, please 
      email: journals.permissions@oup.com.
FAU - Cho, Soo-Kyung
AU  - Cho SK
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Song, Yeo-Jin
AU  - Song YJ
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Kim, Hye Won
AU  - Kim HW
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Nam, Eunwoo
AU  - Nam E
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
FAU - Jeon, Ja-Young
AU  - Jeon JY
AD  - Pfizer Pharmaceuticals Korea Ltd, Seoul, Korea.
FAU - Yoo, Hyun-Jeong
AU  - Yoo HJ
AD  - Pfizer Pharmaceuticals Korea Ltd, Seoul, Korea.
FAU - Sung, Yoon-Kyoung
AU  - Sung YK
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Republic of Korea.
LA  - eng
SI  - ClinicalTrials.gov/NCT02602704
PT  - Journal Article
DEP - 20240215
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
SB  - IM
OTO - NOTNLM
OT  - effectiveness
OT  - rheumatoid arthritis
OT  - tofacitinib
OT  - tumour necrosis factor inhibitor
EDAT- 2024/02/17 12:44
MHDA- 2024/02/17 12:44
CRDT- 2024/02/17 02:41
PHST- 2023/09/21 00:00 [received]
PHST- 2024/01/09 00:00 [revised]
PHST- 2024/01/25 00:00 [accepted]
PHST- 2024/02/17 12:44 [medline]
PHST- 2024/02/17 12:44 [pubmed]
PHST- 2024/02/17 02:41 [entrez]
AID - 7609048 [pii]
AID - 10.1093/rheumatology/keae109 [doi]
PST - aheadofprint
SO  - Rheumatology (Oxford). 2024 Feb 15:keae109. doi: 10.1093/rheumatology/keae109.